FDA approves ramucirumab plus erlotinib for first-line metastatic NSCLC

Trial

RELAY

Drugs

CYRAMZA (ramucirumab) · Anti-VEGFR antibody, erlotinib · EGFR inhibitor

Condition

Thoracic